Last updated: May 29, 2026

Examiner: JIANG, DONG

Tech Center 1600 • Art Units: 1646 1674

This examiner grants 44% of resolved cases

Performance Statistics

44.4%

Allow Rate

-15.6% vs TC avg

621

Total Applications

+54.6%

Interview Lift

1286

Avg Prosecution Days

Based on 610 resolved cases, 2023–2026

0.8%

§101 Eligibility

13.2%

§102 Novelty

49.0%

§103 Obviousness

27.2%

§112 Clarity

App #	Title	Status	Assignee
17188648	VACCINES WITH INTERLEUKIN-33 AS AN ADJUVANT	Non-Final OA	Inovio Pharmaceuticals, Inc.
17897946	TREATMENTS FOR ATOPIC DERMATITIS	Non-Final OA	Chugai Seiyaku Kabushiki Kaisha
18045534	METHOD OF TREATING DISEASES USING AN IL-17 RECEPTOR ANTIBODY FORMULATION	Non-Final OA	Amgen K-A, Inc.
16771948	PEPTIDE IMMUNOGENS OF IL-31 AND FORMULATIONS THEREOF FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS	Final Rejection	UBI US Holdings, LLC.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.